RxDoctor Payments Data

Tariq Khan, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1831112473

Payments from drug & device makers

$1,119in general payments, 2019–2025

Across 38 payments — averaging $29.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$178
  • Corcept Therapeutics$125
  • Medtronic$125
  • AstraZeneca$108
  • Insulet Corporation$97
  • Novo Nordisk$63
  • plus $423 from 10 others

What the payments were for

  • Food & beverage$1,10799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,119 in reported general payments places this provider in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$38,850
Medicare patients
117
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$240,400
TrulicityDulaglutide91$165,487
JardianceEmpagliflozin106$133,376
MounjaroTirzepatide33$42,029
Humulin R U-500 KwikpenInsulin Regular, Human20$37,067
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$27,990
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog51$27,920
Tresiba Flextouch U-100Insulin Degludec46$27,210
Lantus SolostarInsulin Glargine,hum.Rec.Anlog135$26,882
FarxigaDapagliflozin Propanediol24$15,550
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$15,210
JanuviaSitagliptin Phosphate14$11,872
Tresiba Flextouch U-200Insulin Degludec13$10,998
Insulin Lispro Kwikpen U-100Insulin Lispro44$9,463
Humalog Kwikpen U-100Insulin Lispro38$8,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$63$244,240156 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$61$214,156152 claims
Boehringer IngelheimJardiance$27$133,376106 claims
AstraZenecaFarxiga$108$15,55024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →